The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akebia Therapeutics, Inc. alleging that the Company violated federal securities laws.
Class Period: June 28, 2018 to September 2, 2020
Lead Plaintiff Deadline: May 13, 2022
No obligation or cost to you.
Akebia Therapeutics, Inc. NEWS – AKBA NEWS
CLASS ACTION CASE DETAILS: The filed complaint alleges that Akebia Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s lead investigational product candidate, vadadustat, was not as safe in treating non-dialysis dependent chronic kidney disease patients with anemia as defendants had represented; (ii) as a result, defendants overstated the clinical prospects of a Phase 3 clinical program for vadadustat; (iii) accordingly, defendants also overstated vadadustat’s overall commercial and regulatory prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Akebia you have until May 13, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
NO COST TO YOU: If you purchased Akebia securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
New York, NY 10118
Telephone: (212) 616-4899